There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Rezolute (RZLT – Research Report), TG Therapeutics (TGTX – Research Report) and Harpoon Therapeutics (HARP – Research Report) with bullish sentiments.
Rezolute (RZLT)
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Rezolute today and set a price target of $14.00. The company’s shares closed last Friday at $1.55, close to its 52-week low of $1.34.
According to TipRanks.com, Tsao is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Rezolute with a $7.80 average price target, a 403.2% upside from current levels. In a report issued on September 15, JMP Securities also reiterated a Buy rating on the stock with a $8.00 price target.
See the top stocks recommended by analysts >>
TG Therapeutics (TGTX)
In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on TG Therapeutics, with a price target of $41.00. The company’s shares closed last Friday at $10.14.
According to TipRanks.com, White has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
TG Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $26.14.
Harpoon Therapeutics (HARP)
According to TipRanks.com, Nochomovitz is a 4-star analyst with an average return of
Currently, the analyst consensus on Harpoon Therapeutics is a Moderate Buy with an average price target of $33.88, implying a 525.1% upside from current levels. In a report issued on September 14, H.C. Wainwright also maintained a Buy rating on the stock with a $7.50 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RZLT:
